Cellular and Molecular Adaptations to Exercise-induced Inflammatory Response in Children With Autoimmune Diseases

University Hospital, Clermont-Ferrand20 enrolled

Overview

Juvenile idiopathic arthritis (JIA) is a chronic disease characterized by persistent joint inflammation. The immune system disruption that leads to overproduction of pro-inflammatory cytokines (TNF-α, IL-1, IL-6) is a cascade of events on different levels-some molecular, some cellular, and some systemic. Our objective is to identify the mechanisms through which physical activity is liable to mediate inflammatory balance in autoimmune disease settings, and specifically in JIA patients.

Feasibility study

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Juvenile Idiopathic Arthritis

Interventions

Controlled physical activityPROCEDURE

Eligibility

Sex: ALLMin age: 8 YearsMax age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Children between 8 and 12 years * Tanner stage \< T2 * polyarthritis, oligoarthritis and ERA sub-type of JIA * Stable disease during 3 months before starting study Exclusion Criteria: * Infection * Fever * Anti-IL6 treatment * More than 6h per week of physical activity * Systemic corticosteroid treatment during the 3 months before starting study * Systemic JIA * JIA not mastered by treatments * Other autoimmunity or auto-inflammatory diseases * Participation in another clinical research protocol

Locations (1)

CHU de Clermont-Ferrand

Clermont-Ferrand, France

RECRUITING

Outcomes

Primary Outcomes

Percent change

Percent change, before and after a controlled session of physical activity session, of serum and secretion kinetics of IL-6 and its soluble receptors (sIL- 6R and sgp130)

Time frame: AT DAY 1

Secondary Outcomes

pain (VAS)

to assess slipping quality

Time frame: at day 1

locomotors function (CHAQ)

to assess slipping quality

Time frame: at day 1

swelling of knee

to assess slipping quality

Time frame: at day 1

rate of miRNA

to assess slipping quality

Time frame: at day 1

plasma level of melatonin

to assess slipping quality

Time frame: at day 1

sitfness of knee

to assess slipping quality

Time frame: at day 1

Central Contacts

Patrick LACARIN

CONTACT

04 73 75 11 95 placarin@chu-clermontferrand.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.